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Connect ive t issue diseases (CTD) are character ized by disease manifestat ions in
several  organs and the presence ofcirculat ing autoant ibodies tonon-organspecif ic
ant igens, in part icular nuclear ant igens. Al though the pathogenesis of CTD is as
yet only part ial ly elucidated, immunological ly rnediated damage of the
microvasculature is commonly suggested to be one of the major mechanisms.
This theory is supported by the high prevalence of Raynaud's phenomenon and
the presence of morphological  abnormal i t ies of the capi l lar ies in kidney, skin,
nai l fold and lung t issue of pat ients with systemic lupus erythematosus (SLE) and
scleroderma. In addit ion, per ivascular mononuclear inf i l t rates have been
demonstrated in lung t issue specimens of pat ients with scleroderma, suggest ing
that microvascular damage may also play a role in pulmonary involvement in
connect ive t issue diseases. However,  this has not been f i rmly establ ished. In
SLE,  pa tho log ica l  s tud ies  have no t  shown cons is ten t  resu l ts .  Pu lmonary  immune
complex deposit ions have been found but could not be conf irmed in other studies.
Given the simi lar i t ies between the cl in ical  course of interst i t ia l  lung involvement
in SLE and scleroderma, the fact that a scleroderrna-l ike connect ive t issue disease
pattern, including interst i t ia l  lung disease, can occur in chronic graft  versus host
disease may suggest hat pulmonary involvement is an i rnrnunological  process
with a pivotal  role for the T- lyrnphocyte in both scleroderrna nd SLE. This
would be compatible with the fact that lymphocyte alveol i t is,  as ref lected by a
high number of lymphocytes in the bronchoalveolar lavage (BAL) f lu id,  is a
common abnormal i ty in pat ients with scleroderma nd SLE.
In this thesis,  interst i t ia l  pulmonary involvement in pat ients with CTD was
studied in order to elaborate the hypothesis that i rnmunological ly mediated
microvascular damage is the main pathophysiologic rnechanism. Sensit ive lung
funct ion test ing, specif ical ly assessment of the pulmonary di f fusing capacity
(Tr,co) and i ts components Dm and Vc, and bronchoalveolar lavage were ut i l ized
to assess pulnronary involvement.  Morphological  evidence of microvascular
damage was assessed by nai l fold capi l lary microscopy. As a reference for the
studies of BAL in scleroderma nd SLE, a study of two relat ively common
variet ies of ILD, represent ing both ends of the spectrum of lymphocyte and
neutrophi l  alveol i t is,  i .e.  sarcoidosis and idiopathic pulmonary f ibrosis ( IPF),
respect ively,  is incorporated in this thesis.
In the f i rst  part  of  this thesis three studies of pat ients with var ious forms of CTD
or in var ious stages of the development of CTD are described.
Chapter I  descr ibes the results of a prospect ive, longitudinal study with a
fol low-up of 6 years in a group of pat ients with RP, both with and without an
underly ing CTD. We found that pulrnonary funct ion abnormal i ty is a rare f inding
in pat ients with RP without a diagnosis of an underly ing CTD. Pat ients with sero-
logic immunological  abnorrnal i t ies, however,  had lower values of pulmonary
funct ion than pat ients without a posit ive test for autoant ibodies, especial ly with
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respect o T1.66. We concluded that pulmonary funct ion test ing in every pat ient
presenting with RP without an underlying CTD does not appear clinically
justifiable, in view of the low prevalence of pulrnonary function abnormalities in
these patients and the absence of deterioration of pulmonary function. Only
pat ients who exhibi t  immunological  abnormal i t ies, i .e.  autoant ibodies, may be
selected for pulmonary function testing and follow-up, since they are probably
the ones at risk for developing a CTD with pulmonary involvement.
In Chapter 2 we investigated whether functional evidence of pulmonary vascular
damage is associated with extrapulmonary morphological vascular abnormalities
observed at the nai l fold capi l lar ies. In a study populat ion consist ing ofpat ients
with RP at var ious stages in the disease spectrum from primary RP to RP with a
ful lblown CTD, we found that Vc, the component of Tr,ao represent ing the
pulmonary capi l lary blood volume, was below normal in 4l  percent of pat ients
with pr imary RP and undif ferent iated CTD (vs 53 % in scleroderma). Dm,
representing the diffusing capacity of the alveolocapillary membrane and related
to structural changes in the mebrane, was below normal in only 5 % and26 7o of
pat ients with pr imary RP and undif ferent iated CTD, respect ively.  In pat ients with
Scleroderma or the CREST syndrome Dm was signi f icant ly decreased as
compared to the former groups. Dm was also the pulmonary funct ion parameter
which correlated with both nai l fold capi l lary abnormal i t ies and the presence of
ant inuclear ant ibodies. These data led us to conclude that ear ly pulmonary
involvement in scleroderma-syndromes is funct ional ly character ized by a lowered
Dm, correlat ing with morphological  changes of the nai l fold capi l lar ies.
Decreased Vc may probably ref lect Raynaud's phenomenon of the pulmonary
vasculature.
Chapter 3 descr ibes a simi lar study in a large group of pat ients with SLE,
hypothesizing that patients with SLE and ILD represent an overlap of SLE and
scleroderma nd that microvascular damage is involved in the pathophysiology
of ILD in both diseases. Indeed, we found that isolated impairment of T1,6s was
associated with interst i t ia l  changes on chest X-ray and that the presence ofsclero-
dermatous changes of the hands was associated with a restr ict ive lung funct ion
pattern. Nai l fold capi l lary abnonnal i t ies correlated with decreased T1.69 and
Dm, the component of T1,g9 represent ing the di f fusing capacity of the alveoloca-
pi l lary membrane. Ant ibodies to U1-RNA were associated with restr ict ive lung
funct ion and decreased T1,6s. We concluded that interst i t ia l  lung disease is
present in a subset of SLE patients characterized by an increased prevalence of
scleroderma trai ts and ant i-(Ul)RNA ant ibodies. Our data also suggested that
microvascular changes contr ibute to the development of interst i t ia l  ung disease
in SLE as wel l  as in scleroderma.
In chapter 4 a case report  of  a pat ient with SLE and pulmonary hypertension
i l lustrates that an inf lammatory component may also contr ibute to an increase in
pulmonary vascular esistence leading to pulmonary hypertension. In the pat ient
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in marked cl in ical  improvernent and part ial  improvement of pulmonary hyperten-
sion as documented by repeated hemodynamic evaluat ions.
In summary, our data show that ILD is increasingly prevalent in successive
stages in the development of a CTD and that it follows a slowly progressive
course. Funct ional parameters of pulmonary microvascular damage, i .e.
decreased T1,g9 and Dm, were associated with the presence of morphological
changes of the nai l fold capi l lar ies and with the presence of autoant ibodies in both
scleroderma and SLE. These findings are compatible with a major role for
immunological ly mediated microvascular damage in the pathogenesis of ILD in
pat ients with a connect ive t issue disease. The presence of Raynaud's phenomenon
does not warrant rout ine lung funct ion test ing, al though fol low-up is indicated,
in part icular in pat ients with ant inuclear ant ibodies, in view of the possible
development of a CTD.
In the second part  of  this thesis we present two studies on the cel lular
character ist ics of the inf lammatory process in the lungs of pat ie nts with SLE and
scleroderma, as wel l  as the possibi l i ty of  therapeut ic intervent ion with
D-penici l lamine in the lat ter,  introduced by a study in two other types of ILD,
represent ing both ends of the spectrum of alveol i t is,  i .e.  neutrophi l  alveol i t is in
IPF and lymphocyte alveol i t is in sarcoidosis.  In addit ion a case report  i l lustrates
the diagnost ic use of BAL with determinat ion of cel l  di f ferent iat ion and
lymphocyte phenotypes in pat ients with mult iple ILD-associated iseases.
Chapter 5 descr ibes a study on the relat ionship between BAl-derived and
cl inical  and lung funct ion parameters of ILD in pat ients with IPF and
Sarcoidosis.  Lymphocyte alveol i t is in sarcoidosis was associated with increased
alveolar macrophage (AM) Oi product ion as compared to sarcoidosis with
normal lymphocyte counts. Levels of serum ACE correlated posit ively with AM
Ol product ion. Pat ients with extrapulmonary sarcoidosis had higher CD4/CD8
rat ios in BAL and shorter disease durat ion than those with str ict ly pulmonary
sarcoidosis.  Disease durat ion in sarcoidosis was shorter than in IPF and
correlated inversely with the number of BAL cel ls (r : -0.38),  the relat ive and
abso lu te  number  o f  l ymphocy tes  in  BAL f lu id  ( r : -0 .34  and r : -0 .44 ,
respectively) and the percentage of CD4-positive cells and the CD4ICD8 ratio
( r : -0 .43 ,  and r : -0 .48 ,  respec t ive ly ) .
In pat ients with sarcoidosis,  but not in those with IPF, signi f icant inverse relat i -
onships were observed between O; product ion of BAL cel ls and total  lung
capacity (r :-0.67) and the pulmonary di f fusing capacity Tt,6s (r=-0.50).
Summarizing, our f indings showed that lung lymphocyte phenotypes di f fer
among pat ients with puhnonary and extrapulmonary sarcoidosis and that 02
product ion is upregulated in act ive sarcoidosis.  In addit ion, our f indings suggest
that di f ferent relat ionships between BAL data and lung funct ion in pat ients with
sarcoidosis and IPF may be explained by di f ferences in disease durat ion. In IPF,
disease durat ion is l ikely to be underest imated because of i ts insidious onset and
progression. In sarcoidosis,  the acute presence of extrapulmonary symptoms,
t 3 l
helpful  to establ ish an early diagnosis,  is associated with signi f icant BAL
lymphocytosis and lung funct ion impairment.
In chapter 6 we examined the relationship between peripheral blood and
bronchoalveolar lavage lymphocyte phenotypes and lung function in 19
consecutive patients with SLE. In addition, the relationships between disease
act iv i ty and lung funct ion and lymphocyte phenotypes was evaluated. Tl .co, Kco
and Dm correlated inversely with the numbers of CD8 posit ive cel ls and
CD56/CDll  posi t ive (NK-)cel ls in BAL. Oxygen radical  product ion, both by
stimulated and unstimulated BAL cells and blood PMNs was significantly
increased in SLE. In comparison with healthy controls,  pat ients with SLE had a
lower percentage of CD19 posit ive cel ls in the BAL versus an increased
percentage of these cells in peripheral blood. HLA-Dr expression on CD4 and
CD8 posit ive lung lymphocytes was markedly increased in SLE. Current SLE
disease act iv i ty was not associated with changes in lung or blood lymphocyte
phenotypes or lung funct ion. In conclusion, our data support  he hypothesis of an
important role for the T-lymphocyte in the development of ILD in SLE. No
evidence for local B-cel l  prol i ferat ion was found. Our data do suggest hat an
ongoing cel l -mediated immune response, part icular ly involving CD56/CD11
posit ive NK-cel ls and associated with upregulated local product ion of oxygen
radicals and with impaired pulmonary di f fusing capacity is present in the lungs
in SLE and that this process seems to be independent from general  SLE disease
act iv i ty.
Chapter 7 descr ibes the results of a pi lot  study on the therapeut ic intervent ion
with D-penici l lamine in ILD in pat ients with scleroderma, conducted in a double
blind, placebo-controlled crossover fashion. We found significant effects of
D-penici l lamine on BAL parameters. BAL lymphocytes and eosinophi ls decrea-
sed, both in relat ive and absolute numbers. Lung funct ion assessments showed
an increase in residual volurne relat ive to total  lung capacity (TLC) during
t rea tment  (1 .9% wi thout  D-pen ic i l la rn ine  vs  8 .8% wi th  D-pen ic i l lamine) .  We
also observed benef ic ial  systemic effects of D-penici l lamine, i .e.  a decrease of
HLA-Dr expression on peripheral  blood lymphocytes and a decrease of oxygen
radical  product ion by peripheral  blood polynrorphonuclear cel ls.  We concluded
that,  in this pi lot  study, D-penici l lamine has benef ic ial  ef fects on lung inf lammat-
ion, which may impl icate a long-term favourable effect on the course of
interst i t ia l  lung disease in scleroderma. The favourable results ask for
conf irmation by a mult i -centre study with a longer fol low-up period.
The case report  descr ibed in chapter 8 presents an intr iguing coincidence of
scleroderma, sarcoidosis and myosit is,  and i l lustrates the diagnost ic use of
bronchoalveolar lavage with deterrninat ion of cel l  di f ferent iat ion and lymphocyte
phenotypes in pat ients with rnult ip le ILD-associated iseases.
Taken together,  the results of the studies in the second part  of  this thesis show
that BAL is a valuable diagnost ic and invest igat ional tool  in ILD. Although
experience upto now has led to a certain discr iminat ing power, the results of BAL
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durat ion, lung funct ion and the cl in ical  status of the pat ient.  Fol low-up should be
performed whenever possible in order to gain insight into the relat ionships
between changes in lung inf lammation with progression of the disease and other
parameters, such as lung funct ion. Our results of BAL in pat ients with SLE
suggest hat an ongoing cel l -mediated immune response, part icular ly involving
NK-cel ls may underly the development of ILD in this disease. The results of our
pi lot-study with D-penici l larnine in pat ients with scleroderma lung disease show
that lung inf lammation can be inf luenced by this drug, and raise hopes for a
genuine possibi l l i ty for therapeut ic intervent ion in this increasingly important
cause of mortality in scleroderma.
Overall, the results of the studies presented in this thesis support the hypothesis
that immunologically mediated microvascular damage is an important
pathophysiological  mechanism in the development of ILD in pat ients with a CTD.
In addit ion, our data suggest hat the immunological  mechanism involves an
ongoing alveolitis, characterized by a delayed type hypersensitivity-like reaction
involving NK cel ls and act ivated macrophages in the effector phase, on which,
at least in scleroderma, D-penici l lamine may have a benef ic ial  ef fect.
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